access to medicines

Reacting to the launch of the WHO's Technology Access Pool today, with the support of 30 countries, excluding the UK, Heidi Chow, pharmaceuticals campaigner at Global Justice Now said:

Reacting to reports that today’s Coronavirus Global Response Summit has raised the majority of its €7.5 billion target for the research and development of Covid-19 vaccines and treatments, Heidi Chow of Global Justice Now said:  

“We welcome the funding that has been pledged today and the commitment of the hosts to make any Covid-19 vaccine available, accessible and affordable to all. But what is not clear is how the hosts of today’s summit intend to achieve the aim of universal access. 

The race for a coronavirus vaccine proves big pharma isn't fit for purpose


18 March 2020

As the spread of coronavirus continues unabated, the response of the pharmaceutical industry is being thrust into the spotlight. For years, major public health crises have exposed the fundamental conflict between profit and public health in our pharmaceutical system.

Reacting to the UK government's announcement of additional funding for coronavirus vaccine research (1), Heidi Chow, pharmaceuticals campaigner at Global Justice Now said: "Funding for research into a coronavirus vaccine is vitally important, but the government must apply public interest conditions to this funding to prevent pharmaceutical companies from charging high prices which would restrict widespread access. This is even more the case if aid money is being used to pay for it."

Health campaigners have called for the government to make major changes to the way medicines are researched and developed, after new analysis of the cost of leading cancer drugs to the NHS showed that £458 million was spent in 2017/18 on paying pharmaceutical companies for medicines developed with public funding.

Global protests ahead of Novartis AGM in Switzerland tomorrow. Call for new CEO to clean up company following scandals in Colombia and Greece.

Subscribe to RSS - access to medicines

Latest posts

The race for a coronavirus vaccine proves big pharma isn't fit for purpose


18 March 2020

As the spread of coronavirus continues unabated, the response of the pharmaceutical industry is being thrust into the spotlight. For years, major public health crises have exposed the fundamental conflict between profit and public health in our pharmaceutical system.

Resources

There are currently no published resources available.

Latest news

Reacting to the launch of the WHO's Technology Access Pool today, with the support of 30 countries, excluding the UK, Heidi Chow, pharmaceuticals campaigner at Global Justice Now said:

Reacting to reports that today’s Coronavirus Global Response Summit has raised the majority of its €7.5 billion target for the research and development of Covid-19 vaccines and treatments, Heidi Chow of Global Justice Now said:  

“We welcome the funding that has been pledged today and the commitment of the hosts to make any Covid-19 vaccine available, accessible and affordable to all. But what is not clear is how the hosts of today’s summit intend to achieve the aim of universal access. 

Reacting to the UK government's announcement of additional funding for coronavirus vaccine research (1), Heidi Chow, pharmaceuticals campaigner at Global Justice Now said: "Funding for research into a coronavirus vaccine is vitally important, but the government must apply public interest conditions to this funding to prevent pharmaceutical companies from charging high prices which would restrict widespread access. This is even more the case if aid money is being used to pay for it."